Orchestra BioMed Holdings, Inc. ( OBIO ) NASDAQ Global Market

Cena: 3.17 ( 2.26% )

Aktualizacja 06-24 20:26
NASDAQ Global Market
Branża: Biotechnology
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Informacje o spółce:
Sektor: Zdrowie
Branża: Biotechnology
Zatrudnienie: 56
Giełda: NASDAQ Global Market
Ilość akcji w obrocie: 59%
Ilość akcji: 35 744 000
Debiut giełdowy: 2020-08-04
WWW: https://orchestrabiomed.com
CEO: Mr. David P. Hochman
Adres: 150 Union Square Drive
Siedziba: 18938 New Hope
ISIN: US68572M1062
Opis firmy:

Orchestra Biomed Holdings, Inc. działa jako biomedyczna firma innowacyjna. Flagowi kandydaci na produkty firmy obejmują opłacalną terapię neuromodulacyjną serca (CNT) w leczeniu nadciśnienia; oraz cnota Sirolimus Angioinfusion Balloon (SAB) w leczeniu choroby miażdżycowej. Jego produkty obejmują również scory wolne, które są minimalnie inwazyjnymi rozwiązaniami urządzeń chirurgicznych. Firma odbywa się strategiczna współpraca z Medtronic w zakresie rozwoju i komercjalizacji CNT backbeat w celu leczenia nadciśnienia u pacjentów wywołanych rozrusznikiem serca; oraz strategiczne partnerstwo z Terumo Corporation w celu opracowania i komercjalizacji cnoty SAB w leczeniu choroby tętnic. Orchestra Biomed Holdings, Inc. ma siedzibę w New Hope, Pensylwania.

Wskaźniki finansowe
Kapitalizacja (USD) 121 450 625
Aktywa: 75 319 000
Cena: 3.17
Wskaźnik Altman Z-Score: -3.3
Słaby (wysokie ryzyko bankructwa)
Dywidenda: 0
P/E: -2.0
Ilość akcji w obrocie: 59%
Średni wolumen: 429 401
Ilość akcji 38 312 500
Wskaźniki finansowe
Przychody TTM 2 647 000
Zobowiązania: 29 100 000
Przedział 52 tyg.: 2.37 - 8.87
Piotroski F-Score: 2
Słaby (niska jakość finansowa)
EPS: -1.6
P/E branży: 26.1
Beta: 0.409
Raport okresowy: 2025-08-07
WWW: https://orchestrabiomed.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. David P. Hochman Founder, Chairman of the Board of Directors & Chief Executive Officer 942 000 1975
Mr. Darren R. Sherman Founder, President, Chief Operating Officer & Director 787 000 1971
Mr. Andrew Lawrence Taylor M.B.A. Chief Financial Officer 500 022 1971
Dr. Hans-Peter Stoll M.D., Ph.D. Chief Clinical Officer 0 0
Dr. Yuval Hay Mika D.Sc, Ph.D. GM & Chief Technology Officer of Bioelectronic Therapies 0 1959
Dr. George Papandreou Ph.D. GM & Senior Vice President of Focal Therapies 0 1965
Mr. Bob Laughner Senior Vice President of Regulatory & Quality 0 0
Mr. Juan Lorenzo Senior Vice President of Product Development 0 0
Dr. Avraham Matityahu Fischer M.D. Senior Vice President of Medical Affairs & Innovation 0 1956
Mr. William Reed Little Executive Vice President of Corporate Development & Strategy 0 1971
Wiadomości dla Orchestra BioMed Holdings, Inc.
Tytuł Treść Źródło Aktualizacja Link
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Tops Revenue Estimates Orchestra BioMed Holdings, Inc. (OBIO) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to loss of $0.38 per share a year ago. zacks.com 2025-05-12 22:41:08 Czytaj oryginał (ang.)
Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones NEW HOPE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced financial results for the first quarter ended March 31, 2025, and provided a business update highlighting continued regulatory momentum, disciplined operational execution, and a strengthening clinical development pipeline. globenewswire.com 2025-05-12 20:28:00 Czytaj oryginał (ang.)
Orchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure NEW HOPE, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced continued expansion of its global intellectual property (IP) estate supporting its proprietary AVIM therapy pipeline (formerly known as Cardiac Neuromodulation Therapy or “CNT”). Over the past 12 months, the Company has secured 10 new patents related to treatment of hypertension. The Company has also secured a total of 17 patents covering application of the technology for treatment of heart failure, significantly expanding the reach of its IP platform. globenewswire.com 2025-05-07 12:30:00 Czytaj oryginał (ang.)
Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Orchestra BioMed Holdings, Inc. (OBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2025-05-05 15:05:43 Czytaj oryginał (ang.)
Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon Orchestra BioMed's Virtue ® Sirolimus AngioInfusion Balloon™   (“Virtue SAB”) is the only non-coated drug-eluting balloon system under clinical investigation worldwide and has been awarded multiple FDA Breakthrough Device Designations The Virtue Trial will be the first U.S. IDE head-to-head randomized evaluation of a sirolimus-eluting balloon versus a commercially available paclitaxel-coated balloon (AGENT™) for the treatment of coronary in-stent restenosis (“ISR”) Robust non-inferiority trial is designed to provide a clear pathway to regulatory approval as well as potentially showcase clinical advantages of Virtue SAB With the amended IDE approved by the FDA, Orchestra BioMed is currently targeting initiation of the Virtue Trial during the second half of 2025 NEW HOPE, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that the U.S. Food and Drug Administration (“FDA”) has approved its Investigational Device Exemption (“IDE”) amendment to initiate an updated design of the Company's planned Virtue SAB in the Treatment of Coronary ISR Trial (“Virtue Trial”). globenewswire.com 2025-04-29 13:00:00 Czytaj oryginał (ang.)
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences NEW HOPE, Pa., April 28, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will participate in multiple upcoming institutional investor conferences. globenewswire.com 2025-04-28 20:30:00 Czytaj oryginał (ang.)
Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting FDA recently granted Breakthrough Device Designation to AVIM therapy for use in patients with uncontrolled hypertension at increased cardiovascular risk HRS Satellite Symposium will feature leading experts in electrophysiology, hypertension management and heart failure Presentations will detail clinical results from prior studies demonstrating AVIM therapy's ability to immediately, substantially and persistently reduce systolic blood pressure, as well as improve cardiac function Symposium will also feature presentation on the BACKBEAT global pivotal study Orchestra BioMed is currently enrolling in strategic collaboration with Medtronic, plc (NYSE: MDT) NEW HOPE, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced it will host an industry-sponsored satellite symposium at the Heart Rhythm Society (“HRS”) 2025 Annual Meeting, taking place April 24–27, 2025, in San Diego, California featuring recent advancements in the Company's atrioventricular interval modulation (“AVIM”) therapy program. globenewswire.com 2025-04-23 13:00:00 Czytaj oryginał (ang.)
Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy NEW HOPE, Pa., April 22, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Breakthrough Device Designation (“BDD”) for atrioventricular interval modulation (“AVIM”) therapy. globenewswire.com 2025-04-22 11:00:00 Czytaj oryginał (ang.)
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q4 Loss, Lags Revenue Estimates Orchestra BioMed Holdings, Inc. (OBIO) came out with a quarterly loss of $0.43 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.37 per share a year ago. zacks.com 2025-04-01 00:05:31 Czytaj oryginał (ang.)
Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2024 financial results and provided a fourth quarter business update. globenewswire.com 2025-03-31 20:21:00 Czytaj oryginał (ang.)
Orchestra BioMed to Present at Upcoming Investor Conferences NEW HOPE, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at multiple upcoming investor conferences. globenewswire.com 2025-02-20 10:00:00 Czytaj oryginał (ang.)
Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board NEW HOPE, Pa., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the appointment of Vivek Reddy, M.D., as Executive Chairman of the Company's BACKBEAT Study Steering Committee and Chairman of its Bioelectronic Therapies Scientific Advisory Board. In these roles, Dr. Reddy will provide critical leadership in continuing to execute the BACKBEAT global pivotal study and further develop scientific evidence and clinical value for the Company's bioelectronic therapies portfolio. globenewswire.com 2025-02-18 10:00:00 Czytaj oryginał (ang.)
Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference NEW HOPE, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced a late-breaking oral presentation of data on the benefits of atrioventricular interval modulation (“AVIM”) therapy on patients with diastolic dysfunction at the Technology and Heart Failure Therapeutics (“THT”) 2025 Conference in Boston, Massachusetts. The retrospective analysis of data from the MODERATO II study demonstrated that AVIM therapy significantly improved echocardiographic (“Echo”) markers of diastolic dysfunction, an important component in the development of heart failure, in hypertensive patients. globenewswire.com 2025-02-12 12:43:00 Czytaj oryginał (ang.)
Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors NEW HOPE, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the appointment of Christopher Cleary to its Board of Directors as an independent member, effective as of January 30, 2025. Mr. Cleary brings over three decades of experience in corporate development, mergers, acquisitions, strategic investments and structured R&D collaborations, having significantly impacted the medical technology industry through his strategic leadership and visionary approach. globenewswire.com 2025-02-05 10:00:00 Czytaj oryginał (ang.)
Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare Conference NEW HOPE, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at the Piper Sandler 36th Annual Healthcare Conference being held in New York, NY from December 3-5, 2024. globenewswire.com 2024-11-26 18:05:00 Czytaj oryginał (ang.)
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Tops Revenue Estimates Orchestra BioMed Holdings, Inc. (OBIO) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.38 per share a year ago. zacks.com 2024-11-12 21:10:26 Czytaj oryginał (ang.)
Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update NEW HOPE, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its third quarter 2024 financial results and provided a business update. globenewswire.com 2024-11-12 18:12:00 Czytaj oryginał (ang.)
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Lags Revenue Estimates Orchestra BioMed Holdings, Inc. (OBIO) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.35 per share a year ago. zacks.com 2024-08-12 22:36:09 Czytaj oryginał (ang.)
Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update NEW HOPE, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its second quarter 2024 financial results and provided a business update. globenewswire.com 2024-08-12 20:20:00 Czytaj oryginał (ang.)
Orchestra BioMed Holdings, Inc. (OBIO) Loses -25.35% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner Orchestra BioMed Holdings, Inc. (OBIO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. zacks.com 2024-08-08 14:35:24 Czytaj oryginał (ang.)
Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Should You Buy? Orchestra BioMed Holdings, Inc. (OBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2024-08-01 15:05:56 Czytaj oryginał (ang.)
Orchestra BioMed Holdings, Inc. (OBIO) Upgraded to Buy: Here's What You Should Know Orchestra BioMed Holdings, Inc. (OBIO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com 2024-07-26 17:01:09 Czytaj oryginał (ang.)
Wall Street Analysts Believe Orchestra BioMed Holdings, Inc. (OBIO) Could Rally 102.61%: Here's is How to Trade The average of price targets set by Wall Street analysts indicates a potential upside of 102.6% in Orchestra BioMed Holdings, Inc. (OBIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. zacks.com 2024-07-26 14:55:30 Czytaj oryginał (ang.)
Orchestra BioMed Holdings, Inc. (OBIO) Stock Jumps 7.3%: Will It Continue to Soar? Orchestra BioMed Holdings, Inc. (OBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. zacks.com 2024-06-24 13:10:21 Czytaj oryginał (ang.)
All You Need to Know About Orchestra BioMed Holdings, Inc. (OBIO) Rating Upgrade to Buy Orchestra BioMed Holdings, Inc. (OBIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com 2024-06-03 17:01:25 Czytaj oryginał (ang.)
Does Orchestra BioMed Holdings, Inc. (OBIO) Have the Potential to Rally 135.64% as Wall Street Analysts Expect? The consensus price target hints at a 135.6% upside potential for Orchestra BioMed Holdings, Inc. (OBIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. zacks.com 2024-06-03 14:56:13 Czytaj oryginał (ang.)
Orchestra BioMed to Participate in Jefferies Global Healthcare Conference NEW HOPE, Pa., May 22, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at the Jefferies Global Healthcare Conference being held in New York, NY, June 4-6, 2024. globenewswire.com 2024-05-22 12:43:00 Czytaj oryginał (ang.)
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Misses Revenue Estimates Orchestra BioMed Holdings, Inc. (OBIO) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.40 per share a year ago. zacks.com 2024-05-13 23:06:04 Czytaj oryginał (ang.)
Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update NEW HOPE, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its first quarter 2024 financial results and provided a business update. globenewswire.com 2024-05-13 20:58:00 Czytaj oryginał (ang.)
Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents NEW HOPE, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the patent estate related to AVIM Therapy has reached 110 patents worldwide. The most recent patent was issued today, April 30, 2024. globenewswire.com 2024-04-30 12:30:00 Czytaj oryginał (ang.)
Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update NEW HOPE, Pa., March 27, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2023 financial results and provided a fourth quarter business update. globenewswire.com 2024-03-27 18:17:00 Czytaj oryginał (ang.)
Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors NEW HOPE, Pa., March 26, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the appointment of David Pacitti to its Board of Directors, effective as of March 26, 2024. Mr. Pacitti is currently the President of Siemens Medical Solutions USA, Inc. and Head of the Americas, Siemens Healthineers. Prior to joining Siemens Healthineers, he was Division Vice President of U.S. Commercial Operations, Sales, and Marketing at Abbott Vascular, overseeing the company's business in North America. As a member of the Senior Executive Staff, he worked with the CEO, CFO, and Research & Development team on business development initiatives and played pivotal roles in key launches, including Abbott Vascular's first drug-eluting stent and structural heart franchise. globenewswire.com 2024-03-26 10:00:00 Czytaj oryginał (ang.)
Orchestra BioMed to Participate in Upcoming Investor Conferences NEW HOPE, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at multiple conferences throughout March 2024. globenewswire.com 2024-03-07 10:00:00 Czytaj oryginał (ang.)
Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients NEW HOPE, Pa., March 06, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the presentation of new clinical data from a pressure-volume (“PV”) loop study of atrioventricular interval modulation (“AVIM”) therapy (also known as BackBeat CNT™) in pacemaker-indicated patients with uncontrolled hypertension despite the use of antihypertensive medication. These data demonstrate the favorable impact of AVIM therapy compared to standard right ventricular (RV) pacing on systolic blood pressure and overall cardiac function when delivered using both conduction system andstandard pacing lead locations. The PV loop study was conducted at Na Homolce Hospital in Prague by Prof. Petr Neužil, M.D. and the data were featured in an oral presentation at the Technology and Heart Failure Therapeutics (“THT”) 2024 Meeting by Prof. Karl-Heinz Kuck, M.D., Medical Director at LANS Cardio Hamburg. globenewswire.com 2024-03-06 10:37:00 Czytaj oryginał (ang.)